• Pneumococcal bacteria are one of the most common causes of pneumonia. (medlineplus.gov)
  • Meningitis, bacteremia, and pneumonia caused by pneumococcal disease can be fatal. (medlineplus.gov)
  • Pneumococcal pneumonia accounts for 10%-25% of all pneumonias and an estimated 40,000 deaths annually (1). (cdc.gov)
  • The incidence of pneumococcal pneumonia can be 3-5 times that of the detected rates of bacteremia. (cdc.gov)
  • Studies indicate that patients with acquired immunodeficiency syndrome (AIDS) are also at increased risk of pneumococcal disease, with an annual attack rate of pneumococcal pneumonia as high as 17.9/1000 (6-8). (cdc.gov)
  • Postlicensuresurveillanceofpneumoniaincidencecan but less specific, diagnosis of bacterial pneumonia that can beusedtoestimatewhetherpneumococcalconjugatevac- be used to monitor the impact of pneumococcal conjugate cines(PCVs)affectincidence.WeusedPoissonregression vaccines (PCVs) on disease incidence ( 2 , 3 ). (cdc.gov)
  • tifying pneumococcal pneumonia is difficult and insensi- Reflecting this diversity, there was little uptake of 7-valent tive. (cdc.gov)
  • Thus, using an endpoint of radiologically confirmed PCV (PVC7) by the Bedouin population before the vaccine alveolar pneumonia (RCAP) can provide a more sensitive, was introduced into the national immunization program in 2009 but moderate use among Jewish children on the Author affiliations: Yale School of Public Health, New Haven, private market. (cdc.gov)
  • Jakarta/Geneva, 30 June 2021 - Up to 4.5 million children across Indonesia will be protected against the most common cause of severe pneumonia every year, after the introduction of Pneumococcal Conjugate Vaccine (PCV) into the country's routine immunisation programme. (unicef.org)
  • The rollout of the pneumococcal conjugate vaccine is a critical step toward protecting children in Indonesia from pneumonia. (unicef.org)
  • The benefits considered critical outcomes in GRADE included prevention of invasive pneumococcal disease (IPD), pneumococcal community-acquired pneumonia, and hospitalizations due to pneumococcal disease. (cdc.gov)
  • Evidence used to evaluate efficacy of PCV13 against IPD and pneumococcal pneumonia was from the randomized placebo-controlled trial (RCT) conducted among approximately 85,000 adults aged ≥65 years in Netherlands (CAPiTA). (cdc.gov)
  • Most studies show that PPSV23 provides some protection against IPD, but studies have reached contradictory conclusions about its ability to prevent nonbacteremic pneumococcal pneumonia (NPP), which causes several hundred thousand illnesses annually in the United States. (infectioncontroltoday.com)
  • The researchers note that results were robust in sensitivity analyses and alternative scenarios, except when low PCV13 effectiveness against nonbacteremic pneumococcal pneumonia was assumed or when greater childhood vaccination indirect effects were modeled. (infectioncontroltoday.com)
  • The ME Association Pneumonia and the Pneumococcal vaccine - do you need this protection? (meassociation.org.uk)
  • Dr Shepherd answers a question about the pneumonia vaccine and provides the information you need to make an informed decision. (meassociation.org.uk)
  • Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases. (nih.gov)
  • The bacterium Streptococcus pneumoniae can cause a type of pneumonia called pneumococcal pneumonia. (nih.gov)
  • Children younger than 5 and adults older than 65 are most susceptible to becoming ill from pneumococcal pneumonia. (nih.gov)
  • While this vaccine protects against pneumococcal meningitis and bloodstream infections, it is unclear how well it protects against bacterial pneumococcal pneumonia. (nih.gov)
  • The newer PCV13 vaccine (13-valent pneumococcal conjugate vaccine), known by the brand name Prevnar 13, protects against bacterial pneumonia and other invasive pneumococcal illnesses in children, but the efficacy and most effective dosage in adults is unknown. (nih.gov)
  • In adults, pneumococcal pneumonia is the most common type of pneumococcal disease, and pneumococcus is the most common bacterial cause of pneumonia that results in hospitalization ( 3 ). (cdc.gov)
  • By receiving the pneumococcal vaccine, these vulnerable populations can significantly reduce their risk of developing pneumonia. (total-health-care.com)
  • The pneumococcal vaccine helps prevent pneumonia by providing immunity against the most common strains of pneumococcus. (total-health-care.com)
  • The pneumococcal vaccine is especially important for infants and young children, as they are more susceptible to severe forms of pneumonia. (total-health-care.com)
  • KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. (merck.com)
  • and meningitis (infection of the coverings of the brain and spinal cord), as well as non-invasive pneumonia (when pneumococcal disease is confined to the lungs). (merck.com)
  • Pneumococcal infections are globally the most frequent vaccine-preventable cause of death [ 1 ], and community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae is the main burden of pneumococcal disease in the elderly [ 2 ]. (ersjournals.com)
  • Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. (pfizer.com)
  • When these bacteria enter the body they can cause pneumococcal pneumonia, which is an infection of the lungs. (hnhu.org)
  • Children who get pneumonia from the pneumococcal bacteria will have a fever and cough that may bring up thick mucous. (hnhu.org)
  • Pneumococcal conjugate vaccines (PCV), which protect against the main cause of pneumonia, are complex to develop and produce. (gavi.org)
  • Researchers at Karolinska Institutet have identified a new vaccine candidate against pneumococci, bacteria that can cause pneumonia, sepsis, and meningitis. (nordiclifescience.org)
  • Both PCV7, PCV10 and PCV13 are licensed for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by the respective vaccine serotypes of S. pneumoniae in infants and children from 6 weeks to 5 years of age. (who.int)
  • Sputum Gram stain from a patient with a pneumococcal pneumonia. (medscape.com)
  • However, risks of contracting pneumonia can be reduced with a pneumococcal vaccine, as well as maintaining a healthy lifestyle and diet 6 . (doctoroncall.com.my)
  • As such, immunisation against pneumococcal pneumonia is recommended for the elderly to ensure that they are protected against this disease 4 . (doctoroncall.com.my)
  • As people with cardiovascular disease also are at higher risk of contracting pneumococcal pneumonia 5 , immunisation against pneumococcal pneumonia is vital in protecting yourself 1 . (doctoroncall.com.my)
  • As smokers have been found to be at higher risk of getting pneumonia, they are encouraged to consider immunisation against vaccine-preventable diseases such as pneumococcal pneumonia 3 . (doctoroncall.com.my)
  • This free mobile app gives clinicians patient-specific pneumococcal vaccination recommendations from anywhere at any time. (cdc.gov)
  • See Pneumococcal Vaccination: Summary of Who and When to Vaccinate for CDC guidance on vaccination options for adults who have previously received a pneumococcal conjugate vaccine. (cdc.gov)
  • See Pneumococcal Vaccination: Summary of Who and When to Vaccinate for all pneumococcal vaccine recommendations by vaccine and age. (cdc.gov)
  • The national vaccination program started vaccinating newborns in 2004 with the 7-valent pneumococcal conjugate vaccine (PCV 7). (wikipedia.org)
  • In late 2020 a start was made with the vaccination of care home residents with the 23-valant pneumococcal polysaccharide vaccine (PPV 23). (wikipedia.org)
  • The national vaccination program started including the pneumococcal vaccine for newborns in April 2006. (wikipedia.org)
  • A computer-based cost-effectiveness analysis suggests that use of the 13-valent pneumococcal conjugate vaccine (PCV13) might prevent more pneumococcal disease compared with the current 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccination recommendations, while remaining economically reasonable, although the authors note that their findings are sensitive to a number of assumptions, according to a study in the Feb. 22/29 issue of JAMA. (infectioncontroltoday.com)
  • Kenneth J. Smith, MD, MS, of the University of Pittsburgh School of Medicine, and colleagues conducted a study to estimate the effectiveness and cost-effectiveness of pneumococcal vaccination strategies among adults 50 years of age and older. (infectioncontroltoday.com)
  • indirect (herd immunity) effects resulting from childhood PCV13 vaccination were extrapolated based on observed 7-valent pneumococcal conjugate vaccine (PCV7) effects. (infectioncontroltoday.com)
  • With no vaccination, the estimated lifetime risk from age 50 years onward for hospitalized NPP was 9.3 percent, for IPD was 0.86 percent, and for death due to pneumococcal disease was 1.8 percent. (infectioncontroltoday.com)
  • We have a new free leaflet on this year's Flu Vaccination, and a Website Poll asking you about any reactions you might have had to the vaccine. (meassociation.org.uk)
  • For more information, see Pneumococcal Advisory Committee on Immunization Practices Vaccine Recommendations and Centers for Disease Control and Prevention (CDC): Pneumococcal Vaccination . (merckmanuals.com)
  • For detailed information on administering the pneumococcal vaccine to children see CDC: Pneumococcal Vaccination: Summary of Who and When to Vaccinate and CDC: Child and Adolescent Immunization Schedule by Age ). (merckmanuals.com)
  • Vaccination is the most effective way to prevent pneumococcal meningitis and its devastating consequences. (total-health-care.com)
  • Vaccination is particularly important for infants, as they are at a higher risk of developing pneumococcal meningitis. (total-health-care.com)
  • By reducing the risk of pneumococcal bacteremia, vaccination can significantly lower the chances of developing sepsis and its life-threatening consequences. (total-health-care.com)
  • The Centers for Disease Control and Prevention (CDC) provides recommendations regarding pneumococcal vaccination for different age groups and high-risk individuals. (total-health-care.com)
  • Vaccination with VAXNEUVANCE may not protect all vaccine recipients. (merck.com)
  • Pneumococcal conjugate vaccines (PCVs), which were primarily developed for vaccination of infants under 2 years of age, have significantly decreased invasive pneumococcal diseases worldwide in all age groups by herd protection effects [ 5 , 6 ]. (ersjournals.com)
  • PCV7 was replaced by either the 10-valent conjugate vaccine or, mainly, PCV13 in the German infant vaccination programme in 2010. (ersjournals.com)
  • In adults, the German Standing Committee on Immunization (STIKO) recommends the 23-valent pneumococcal polysaccharide vaccine (PPV23) as routine pneumococcal vaccination for all adults of 60 years and above and for all patients with defined chronic comorbidities predisposing to pneumococcal disease, regardless of age. (ersjournals.com)
  • In Sept. 2014, the Centers for Disease Control and Prevention (CDC) released recommendations for the use of two pneumococcal vaccines for routine vaccination of healthy adults age 65 years and older. (immunize.org)
  • Despite widespread vaccination, 4 million pneumococcal disease cases remain annually in the U.S. as well as 22,000 related deaths, they added. (contagionlive.com)
  • For more information, see the Centers for Disease Control and Prevention's (CDC) Pneumococcal Vaccination: What Everyone Should Know , Pneumococcal Conjugate (Interim) vaccine information statement , and Pneumococcal Polysaccharide vaccine information statement . (msdmanuals.com)
  • Children up to 18 years of age should receive the pneumococcal vaccine, usually in 4 doses at ages 2 months, 4 months, 6 months, and 12 to 15 months, as a part of the routine vaccination schedule recommended for children (see CDC: Child and Adolescent Immunization Schedule by Age ). (msdmanuals.com)
  • A pneumococcal vaccine has been included in Sweden's childhood vaccination programme since 2009. (nordiclifescience.org)
  • Since childhood vaccination was introduced, the incidence of severe pneumococcal infections in infants has decreased, an effect that has not been observed in adults. (nordiclifescience.org)
  • The vaccine is given to children as part of the routine vaccination schedule with the first dose of PCV given at the age of 6 weeks or 2 months (depending on the national schedule), followed by 2 doses at one to two months intervals. (who.int)
  • Globally, pneumococcal vaccination has been routinely incorporated into childhood immunisation schedules. (medicalchannelasia.com)
  • Adults who received PCV13 have options on how to complete their pneumococcal vaccine series. (cdc.gov)
  • A second dose of PPSV23, and another type of pneumococcal vaccine called PCV13, are recommended for certain high-risk groups. (medlineplus.gov)
  • GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among adults aged ≥65 years. (cdc.gov)
  • The intervention evaluated was a single dose of PCV13 compared to a dose of 23-valent polysaccharide vaccine (PPSV23). (cdc.gov)
  • The pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23) protect against pneumococcal infections. (kidshealth.org)
  • PCV13 protects against 13 types of pneumococcal bacteria, which cause the most common pneumococcal (new-muh-KOK-uhl) infections in kids. (kidshealth.org)
  • The effectiveness of the PCV13 vaccine in preventing NPP in adults is currently unknown. (infectioncontroltoday.com)
  • With routine vaccine administration at ages 50 and 65 years, it was estimated that PCV13 costs $45,100 per QALY compared with PCV13 substituted in current recommendations. (infectioncontroltoday.com)
  • Model estimates of the effect of adult PCV13 would be strengthened by evidence of PCV13 effectiveness against NPP from ongoing clinical trials and availability of data on the indirect effects of childhood PCV13 on adult pneumococcal disease rates, the authors conclude. (infectioncontroltoday.com)
  • Earlier studies suggest that PCV13 may not induce as strong an immune response in older adults who previously received the PPSV23 vaccine within the past 5 years as in those who have not. (nih.gov)
  • The first group, 294 participants who have never been vaccinated with the PPSV23 vaccine will receive a single 0.5 milliliter (mL) injection of the PCV13 vaccine. (nih.gov)
  • The second group, 588 participants who were vaccinated with the PPSV23 vaccine three to seven years before study enrollment, will be randomized to receive one 0.5 mL injection of the PCV13 vaccine or 1.0 mL of the PCV13 vaccine administered as two 0.5 mL injections, one in each arm. (nih.gov)
  • The researchers will also evaluate whether the larger, 1.0 mL, dose of PCV13 is more immunogenic than the 0.5 mL dose in participants who were previously vaccinated with the PPSV23 vaccine. (nih.gov)
  • Before 2021, ACIP recommended 23-valent pneumococcal polysaccharide vaccine (PPSV23) alone (up to 2 doses), or both a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) in combination with 1-3 doses of PPSV23 in series (PCV13 followed by PPSV23), for use in U.S. adults depending on age and underlying risk for pneumococcal disease. (cdc.gov)
  • In addition, ACIP recommends use of either a single dose of PCV20 or ≥1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses. (cdc.gov)
  • Shared clinical decision-making is recommended regarding use of a supplemental PCV20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both PCV13 and PPSV23. (cdc.gov)
  • For Germany, we have described earlier the distribution of vaccine serotypes covered by the first but no longer available 7-valent pneumococcal conjugate vaccine (PCV7) and the 13-valent conjugate vaccine (PCV13) between 2002 and 2016 in adult patients with CAP enrolled into the prospective multicentre study CAPNETZ [ 8 , 9 ]. (ersjournals.com)
  • Administer one dose of pneumococcal conjugate vaccine (PCV13, Prevnar13®, Pfizer) to people age 65 years and older if they have not received a dose in the past. (immunize.org)
  • Administer one dose of pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®, Merck) one year following the PCV13 dose. (immunize.org)
  • In Sept. 2014, the second pneumococcal vaccine, PCV13, was added to the routine immunization schedule for healthy adults age 65 years and older . (immunize.org)
  • When the recommendations to give these two pneumococcal vaccines to adults were first issued, the doses of PCV13 and PPSV23 were to be spaced at least six months apart. (immunize.org)
  • The Vietnam Pneumococcal Trial II (VPT-II) will evaluate reduced-dose schedules of PCV10 and PCV13 utilising an unvaccinated control group. (bmj.com)
  • Our study adds evidence that the use of a vaccine in a population, in this case PCV13, by preventing vaccine-type disease and avoidance of antibiotic use, among other factors, appears to be an additional tool to combat antimicrobial resistance," Suaya concluded. (contagionlive.com)
  • The conjugate vaccine PCV13 protects against 13 types of pneumococcal bacteria (pneumococci). (msdmanuals.com)
  • Herein, we demonstrate that 3M-052 is a locally acting lipidated imidazoquinoline TLR7/8 agonist adjuvant in mice, which, when properly formulated, can induce robust Th1 cytokine production by human newborn leukocytes in vitro, both alone and in synergy with the alum-adjuvanted pneumococcal conjugate vaccine 13 (PCV13). (jci.org)
  • In addition, PCV13 is licensed for the prevention of pneumococcal disease in adults >50 years of age. (who.int)
  • PCV13 vaccine protects against 13 pneumococcal bacteria strains that most commonly cause pneumococcal disease, while the PPSV23 protects against 23 strains. (medicalchannelasia.com)
  • GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among immunocompromised children aged 6 through 18 years. (bvsalud.org)
  • Pneumococcal polysaccharide vaccine (PPSV23) can prevent pneumococcal disease . (medlineplus.gov)
  • PPSV23 protects against 23 types of bacteria that cause pneumococcal disease. (medlineplus.gov)
  • People 65 years or older should get a dose of PPSV23 even if they have already gotten one or more doses of the vaccine before they turned 65. (medlineplus.gov)
  • The PPSV23 vaccine has been recommended for prevention of invasive pneumococcal disease (IPD) in adults since 1983, according to background information in the article. (infectioncontroltoday.com)
  • For the past 30 years, the PPSV23 vaccine (23-valent pneumococcal polysaccharide vaccine), known by the brand name Pneumovax 23, has been the standard protection from invasive pneumococcal disease in adults over 65 years of age. (nih.gov)
  • Researchers will evaluate participants' immune responses via blood samples drawn 28 days and 180 days post-injection, to compare responses between those who had previously been vaccinated with the PPSV23 vaccine and those who had not been. (nih.gov)
  • PPSV23 (Pneumovax23) is a 23-valent vaccine that has been recommended for use since the 1980s for persons aged ≥2 years with certain underlying medical conditions and for adults aged ≥65 years ( Table 1 ) (Figure). (cdc.gov)
  • It also seems to confer greater protection against invasive pneumococcal disorders than PPSV23. (merckmanuals.com)
  • The polysaccharide vaccine PPSV23 protects against 23 types of pneumococci. (msdmanuals.com)
  • generally go with PCV20 after at least 1 year to complete the pneumococcal series, instead of PPSV23. (therapeuticresearch.com)
  • PneumoADIP is funded by the Global Alliance for Vaccines and Immunization (GAVI). (wikipedia.org)
  • In May 2017, the Government of India decided to include pneumococcal conjugate vaccine in its Universal Immunization Programme. (wikipedia.org)
  • In order to keep the synthesis effort for the vaccine managable, the researchers identified the smallest possible sugar for immunization. (mpg.de)
  • This report compiles and summarizes all published recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. (cdc.gov)
  • For a summary of changes to the 2023 adult immunization schedule, including new recommendations for the use of PCV15 and PCV20 in people who previously received pneumococcal vaccines, see the Advisory Committee on Immunization Practices Recommended Adult Immunization Schedule, United States, 2023: Changes to the 2023 Adult Immunization Schedule . (merckmanuals.com)
  • Overview of Immunization Immunity can be achieved Actively by using antigens (eg, vaccines, toxoids) Passively by using antibodies (eg, immune globulins, antitoxins) A toxoid is a bacterial toxin that has been modified. (merckmanuals.com)
  • VAXNEUVANCE is indicated in the U.S. for active immunization of adults 18 years of age and older for the prevention of invasive disease caused by the S. pneumoniae serotypes contained in the vaccine. (merck.com)
  • The pneumococcal vaccine is available free of charge to Canadians aged 65 and older and is part of provinces' routine immunization programs. (yahoo.com)
  • Technically Speaking columns cover practical topics in immunization delivery such as needle length, vaccine administration, cold chain, and immunization schedules. (immunize.org)
  • Universal immunization of BC infants with four doses of conjugate pneumococcal vaccine was introduced in September 2003. (bcmj.org)
  • The National Advisory Committee on Immunization statement on conjugate pneumococcal immunization permits a reduced dose schedule. (bcmj.org)
  • The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. (uzh.ch)
  • The Canadian Paediatric Society and the National Advisory Committee on Immunization strongly recommend routine immunization of infants and young children against pneumococcal disease. (hnhu.org)
  • These data summarize country introduction status of PCV (Pneumococcal conjugate vaccine) in the national immunization programme. (who.int)
  • This potent immunization strategy, potentially effective with one birth dose, could represent a new paradigm in early life vaccine development. (jci.org)
  • Increased efforts to accelerate new and underutilized vaccine introductions are urgently needed to improve universal equitable access to all recommended vaccines to achieve the global Immunization Agenda 2021-2030 (IA2030) targets. (medscape.com)
  • The global Immunization Agenda 2021-2030 (IA2030), by increasing equitable access to and use of new and existing vaccines, envisions a world where everyone everywhere fully benefits from vaccines. (medscape.com)
  • IA2030, endorsed by the World Health Assembly, includes a target to achieve 500 new and underutilized vaccine introductions in low-income and middle-income countries' routine immunization schedules by 2030. (medscape.com)
  • Year WHO recommended inclusion of vaccine in all national routine immunization programs. (medscape.com)
  • International immunization programs for children have many vaccines in common but, depending on the region, may vary slightly. (medscape.com)
  • Another consideration relating to global immunization is the use of travel vaccines. (medscape.com)
  • While an important component of immunization programs, a review of influenza vaccines is beyond the scope of this article. (medscape.com)
  • Hepatitis B (HBV) vaccine is included in routine childhood immunization vaccines to prevent chronic HBV infection. (medscape.com)
  • The objectives of vaccine-preventable disease surveillance in NSW are, at an individual level, to identify events that may require immediate public health control measures and, at a population level, to identify risk factors such as age and geographic location that inform better targeted immunization efforts. (who.int)
  • On June 22, 2023, the CDC's Advisory Committee on Immunization Practices (ACIP) recommended use of 20-valent pneumococcal conjugate vaccine (PCV20 [Prevnar 20, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.]) as an option to 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sh. (bvsalud.org)
  • A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer Respiratory Syncytial Virus (RSV) preF vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on June 21, 2023. (bvsalud.org)
  • Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited serotype coverage, long-lasting protection, and lower cost to be developed. (mdpi.com)
  • In 2021, two new pneumococcal conjugate vaccines (PCVs), a 15-valent and a 20-valent PCV (PCV15 and PCV20), were licensed for use in U.S. adults aged ≥18 years by the Food and Drug Administration. (cdc.gov)
  • However, serotype replacement, i.e. replacement of vaccine serotypes by non-vaccine serotypes, has decreased the serotype coverage of PCVs over time [ 6 , 7 ]. (ersjournals.com)
  • Introduction Reduced-dose schedules offer a more efficient and affordable way to use pneumococcal conjugate vaccines (PCVs). (bmj.com)
  • Currently available PCVs are safe and efficacious and the increased number of serotypes present in these vaccines, compared to the first licensed PCV7, represent significant progress in the fight against pneumococcal morbidity and mortality, in particular from a developing country perspective. (who.int)
  • In addition, adults younger than age 65 years of age may be recommended to receive pneumococcal vaccines. (cdc.gov)
  • See Examples: Complete pneumococcal vaccine schedules for adults [4 pages] for a visual illustration of these vaccine options. (cdc.gov)
  • Treat adults who received PCV7 the same as people who have never received any pneumococcal vaccines. (cdc.gov)
  • Anyone can get pneumococcal disease, but children under 2 years of age, people with certain medical conditions, adults 65 years or older, and cigarette smokers are at the highest risk. (medlineplus.gov)
  • Although no recent data from the United States exist, in the United Kingdom pneumococcal infections may account for 34% of pneumonias in adults who require hospitalization (2). (cdc.gov)
  • The polysaccharide vaccines, while effective in healthy adults, are not effective in children less than two years old or those with poor immune function. (wikipedia.org)
  • Health Canada's general recommendations are 13-valent pneumococcal conjugate vaccine (PCV 13) vaccine for children aged 2 months to 18 years and 23-valent pneumococcal polysaccharide vaccine (PPV 23) vaccine for adults. (wikipedia.org)
  • Children younger than 2 years old, adults over 65, and people with some medical conditions are at high risk for serious pneumococcal infections. (kidshealth.org)
  • The study supported by the National Institutes of Health will compare two dosages of a pneumococcal vaccine approved for children ages 6 weeks to 5 years, and adults 50 and older. (nih.gov)
  • During 2018-2019, approximately 60%-75% of all IPD in adults was caused by the 24 pneumococcal serotypes that were included in the formulations of commercially available polysaccharide conjugate vaccine (PCV) or pneumococcal polysaccharide vaccine (PPSV) vaccines (i.e. (cdc.gov)
  • KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for licensure of V114, Merck's investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older. (merck.com)
  • V114 is Merck's investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults and children. (merck.com)
  • V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease in older adults worldwide and are not contained in the pneumococcal conjugate vaccine currently licensed for use in adults. (merck.com)
  • V114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older. (merck.com)
  • While healthy adults can suffer from pneumococcal disease, patient populations particularly vulnerable to infection include older adults such as those 65 years of age and older, people with HIV, and those with certain chronic health conditions. (merck.com)
  • For the first time, older adults will also have access to the respiratory syncytial virus (RSV) vaccine . (yahoo.com)
  • In the meantime, one dose of Pneu-P-23 vaccine is recommended for adults who are 65 years of age and older to protect them against a severe pneumococcal infection. (yahoo.com)
  • The newest shot to be made available this season is an RSV vaccine, which has been authorized for use in Canada for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older. (yahoo.com)
  • The FDA's acceptance of our application for 20vPnC is yet another significant milestone in Pfizer's continuing efforts to help protect adults against pneumococcal disease," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research and Development, Pfizer. (pfizer.com)
  • The number of severe pneumococcal infections in adults has not decreased significantly and most of the infections are now caused by pneumococcal bacteria that today's vaccines do not protect against. (nordiclifescience.org)
  • Start by using CDC's PneumoRecs VaxAdvisor app or website when a high-risk inpatient needs a pneumococcal vaccine (postsplenectomy, etc)...or if your hospital screens adults before discharge. (therapeuticresearch.com)
  • Access CDC's Pneumococcal Vaccine Timing for Adults for a flowchart. (therapeuticresearch.com)
  • Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report. (streetwisereports.com)
  • Sometime this year, Vaxcyte should hear back on its IND filing for VAX-A1, its vaccine candidate for group A strep in adults and infants. (streetwisereports.com)
  • Addition of the synthetic sugar molecule to the current pneumococcal vaccine Prevnar 13, expanded the protection in vaccinated animals from 13 to 14 serotypes including the dangerous ST8 pathogen. (mpg.de)
  • The Dutch health institute RIVM has stopped the distribution of a batch of Pfizer's Prevnar childhood vaccine following the death of three babies shortly after being vaccinated. (infiniteunknown.net)
  • Continue to use any remaining Prevnar 13 vaccines still on-hand through the expiration date before transiting to PCV15 or PCV20. (phila.gov)
  • Most pneumococcal infections are mild. (medlineplus.gov)
  • These vaccines prevent infections in children who get them, and help stop the infections from spreading to others. (kidshealth.org)
  • yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today. (infectioncontroltoday.com)
  • The pneumococcal vaccine can provide them with an added layer of protection against pneumococcal infections and potentially life-threatening complications. (total-health-care.com)
  • Reduction of Bloodstream Infections: Pneumococcal bacteremia, an infection of the bloodstream, can lead to sepsis, a life-threatening condition. (total-health-care.com)
  • The pneumococcal vaccine helps prevent bloodstream infections by strengthening the immune system's ability to recognize and fight off the pneumococcus bacterium. (total-health-care.com)
  • By receiving the pneumococcal vaccine, these individuals can protect themselves from the potential complications of bloodstream infections and improve their overall health outcomes. (total-health-care.com)
  • The vaccine has been developed to protect against severe infections in children, but only targets a fraction of the close to one hundred different types of pneumococcal bacteria that have been described so far. (nordiclifescience.org)
  • There is an urgent need for new vaccine strategies to protect the elderly from pneumococcal infections," says the study's last author Birgitta Henriques-Normark, professor at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. (nordiclifescience.org)
  • The results suggest that membrane particles can be used as a platform for producing vaccines against pneumococcal infections and perhaps other bacterial infections, and this is something we are now working on. (nordiclifescience.org)
  • Vaccine-preventable disease control is continually strengthening in NSW with notable successes in invasive bacterial infections. (who.int)
  • A pilot Advance Market Commitment (AMC) to develop a vaccine against pneumococcus was launched by GAVI in June 2009 as a strategy to address two of the major policy challenges to vaccine introduction: a lack of affordable vaccines on the market, and insufficient commercial incentives to develop vaccines for diseases concentrated in developing countries. (wikipedia.org)
  • These vaccines have been extensively studied, are currently in human trial phase 1/2, and seem to be the best treatment choice for pneumococcal diseases, especially for developing countries. (mdpi.com)
  • Since the U.S. Food and Drug Administration approved seven-valent pneumococcal conjugate vaccine (PCV7) for children under age 5 in 2000, rates of invasive pneumococcal disease (IPD) have significantly declined in all age groups while rates of IPD caused by non-vaccine strains have increased modestly, according to research presented this week at the 2008 International Conference on Emerging Infectious Diseases in Atlanta. (contemporarypediatrics.com)
  • WEDNESDAY, March 19 (HealthDay News) -- Since the U.S. Food and Drug Administration approved seven-valent pneumococcal conjugate vaccine (PCV7) for children under age 5 in 2000, rates of invasive pneumococcal disease (IPD) have significantly declined in all age groups while rates of IPD caused by non-vaccine strains have increased modestly, according to research presented this week at the 2008 International Conference on Emerging Infectious Diseases in Atlanta. (contemporarypediatrics.com)
  • For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases. (merck.com)
  • For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. (merck.com)
  • The pneumococcal vaccine is a vital preventive measure that can protect individuals from these potentially life-threatening diseases. (total-health-care.com)
  • The pneumococcal vaccine plays a critical role in protecting individuals, particularly those who are more susceptible to pneumococcal diseases. (total-health-care.com)
  • Study co-author Professor Tony Walls, Paediatric Infectious Diseases Specialist at the University of Otago, Christchurch, says the results reinforce the timeliness of Pharmac's decision to switch to the PVC-13 vaccine. (otago.ac.nz)
  • We know some people are already getting these vaccines, but we're just going to see greater access in the days and weeks ahead,' said Dr. Isaac Bogoch, an infectious diseases specialist at Toronto General Hospital. (yahoo.com)
  • How do pneumococcal diseases spread? (hnhu.org)
  • Administration of routine childhood vaccinations (eg, hepatitis, polio, and meningococcal vaccines) is often prioritized over specific travel vaccines, as these diseases are still prevalent in many underdeveloped countries. (medscape.com)
  • Specific travel vaccines (eg, typhoid fever, yellow fever, Japanese encephalitis) are the next consideration, as these diseases are endemic in many resource-limited countries. (medscape.com)
  • It's important to get vaccinated against vaccine-preventable diseases such as pneumococcal disease, as those with asthma are more likely to get health complications 4 . (doctoroncall.com.my)
  • We aim to describe the epidemiology of selected vaccine-preventable diseases in New South Wales (NSW) for 2012. (who.int)
  • Case notification rates for other selected vaccine-preventable diseases remained stable. (who.int)
  • Data describing cases in NCIMS were extracted for selected vaccine-preventable diseases according to the date of onset, with 2012 data compared with data for recent years. (who.int)
  • Pneumococcal disease refers to any illness caused by pneumococcal bacteria. (medlineplus.gov)
  • For many years scientists have used the characteristic sugar molecules on the surface of bacteria as a component of vaccines. (mpg.de)
  • Coupled with carrier proteins, these molecules are effective vaccines that are much simpler to prepare in the laboratory than the isolation of conventional vaccines from bacteria. (mpg.de)
  • Four out of 10 healthy people have pneumococcal bacteria in their mouth, nose and throat without becoming ill. (hnhu.org)
  • The vaccine molecules comprise nano-sized membrane vesicles produced by the bacteria and provide protection in mice, a new study published in PNAS reports. (nordiclifescience.org)
  • In this present study, KI researchers examined the possibility of developing a vaccine based on nano-sized membrane vesicles that pneumococcal bacteria naturally produce from their cell membrane in order to communicate with their surroundings and affect other cells. (nordiclifescience.org)
  • The researchers isolated such vesicles, called membrane particles, from cultivated pneumococcal bacteria. (nordiclifescience.org)
  • Both vaccines are made from inactivated bacteria. (medicalchannelasia.com)
  • The estimated incidence of pneumococcal meningitis is 1-2/100,000 persons. (cdc.gov)
  • Mortality from pneumococcal disease is highest in patients with bacteremia or meningitis, patients with underlying medical conditions, and older persons. (cdc.gov)
  • Recurrent pneumococcal meningitis may occur in patients with cerebrospinal fluid leakage complicating skull fractures or neurologic procedures. (cdc.gov)
  • Protection Against Meningitis: Pneumococcal meningitis is a severe infection that affects the membranes surrounding the brain and spinal cord. (total-health-care.com)
  • Pneumococcal meningitis is a specific type of meningitis caused by the pneumococcus bacterium. (total-health-care.com)
  • The pneumococcal vaccine helps protect individuals from pneumococcal meningitis by stimulating the immune system to produce antibodies against the bacterium. (total-health-care.com)
  • Another 65 young children develop pneumococcal meningitis. (hnhu.org)
  • The inner ear has connections with the brain, through which the infection may spread, causing (Pneumococcal) meningitis. (medicalchannelasia.com)
  • Ask your health care provider.Call your local or state health department.Contact the Centers for Disease Control and Prevention (CDC): Call 1-800-232-4636 ( 1-800-CDC-INFO ) or visit CDC's website at http://www.cdc.gov/vaccines . (medlineplus.gov)
  • 33:273-6, 281) and include new information regarding 1) vaccine efficacy, 2) use in persons with human immunodeficiency virus (HIV) infection and in other groups at increased risk of pneumococcal disease, and 3) guidelines for revaccination. (cdc.gov)
  • The best estimates of the incidence of serious pneumococcal disease in the United States are based on surveys and community-based studies of pneumococcal bacteremia. (cdc.gov)
  • The 23 capsular types in the vaccine cause 88% of the bacteremic pneumococcal disease in the United States. (cdc.gov)
  • The recommended three or four doses are between 71 and 93% effective at preventing severe pneumococcal disease. (wikipedia.org)
  • Under the terms of an AMC, donors make a legally binding guarantee that, if a future vaccine is developed against a particular disease, they will purchase a predetermined amount at an agreed-upon price. (wikipedia.org)
  • The COVID-19 pandemic has raised the profile of vaccines as one of the best tools we have to fight the threat of disease. (unicef.org)
  • [2] Evidence was not available for the critical outcome of hospitalizations due to pneumococcal disease. (cdc.gov)
  • These vaccines are very effective at preventing severe disease, hospitalization, and even death. (kidshealth.org)
  • The pneumococcal vaccines contain only a small piece of the germ and so cannot cause pneumococcal disease. (kidshealth.org)
  • Certain persons with pneumococcal colonization might develop invasive pneumococcal disease (IPD) ( 2 ). (cdc.gov)
  • Ahead of the first fall and winter virus seasons in which vaccines are available for COVID-19, influenza, and respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention is recommending Pfizer's maternal vaccine to protect newborns from severe RSV illness. (contemporarypediatrics.com)
  • Vaccines are directed against many of the serotypes that cause disease. (merckmanuals.com)
  • Certain medical conditions (eg, chronic disorders, immunocompromising conditions, cerebrospinal fluid leaks, cochlear implants) increase the risk of pneumococcal disease. (merckmanuals.com)
  • These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease. (merck.com)
  • Individuals at higher risk of developing pneumococcal bacteremia include those with underlying health conditions, such as diabetes or chronic liver disease. (total-health-care.com)
  • Late last year, in response to concerns raised by child health experts, Pharmac amended the national childhood immunisation schedule to include a 13-valent pneumococcal vaccine (PVC-13) in response to rising case numbers of Invasive Pneumococcal Disease ( IPD ). (otago.ac.nz)
  • Pneumococcal disease is currently the world's number one vaccine-preventable cause of death among infants and children younger than five years of age. (otago.ac.nz)
  • If approved, 20vPnC will cover more serotypes responsible for the majority of pneumococcal disease than any other pneumococcal conjugate vaccine currently licensed or currently in late-stage clinical development. (pfizer.com)
  • There is already a dramatic decline in the rate of invasive pneumococcal disease in those under the age of 5. (bcmj.org)
  • On the basis of this evidence, BC's Communicable Disease Policy Committee has advised that BC follow Quebec, Australia, and the United Kingdom and provide a three-dose schedule of conjugated pneumococcal vaccine beginning January 2007. (bcmj.org)
  • Efficacy of the vaccine was 97.4% for invasive disease caused by a vaccine serotype, for fully vaccinated (four doses) children. (bcmj.org)
  • Vaccine shortages offered an opportunity for the Centers for Disease Control to conduct a case control study comparing the effectiveness of a three-dose series with a four-dose series. (bcmj.org)
  • Invasive pneumococcal disease (IPD) is reportable by physicians and laboratories in BC. (bcmj.org)
  • There will be ongoing efforts to ensure that we are as efficient as possible in providing protection from vaccine-preventable disease. (bcmj.org)
  • Each year in Canada, about 15 children under age five die from serious pneumococcal disease. (hnhu.org)
  • For more information, visit the latest articles about pneumococcal disease . (gavi.org)
  • By the end of 2019, Gavi support had helped countries immunise more than 215 million children across 60 lower-income countries against pneumococcal disease. (gavi.org)
  • Vaccines are directed against many of the types most likely to cause serious disease. (msdmanuals.com)
  • Pneumococcal polysaccharide vaccine (PPV23): this contains containing 23 serotypes of the pneumococcus, which account for 88% of pneumococcal bacteremia disease and cross-react with other types that causes additional 8% of disease. (who.int)
  • The pneumococcal vaccine lowers the risk of being infected with pneumococcal disease, a major cause of morbidity and mortality worldwide. (medicalchannelasia.com)
  • The vaccines induce production of antibodies by the immune system, thereby protecting against disease should there be subsequent infection with Pneumococcus. (medicalchannelasia.com)
  • Design, patients and setting: Ecological analysis of trends in invasive pneumococcal disease (IPD) notification rates and vaccine effectiveness estimation using the screening method, using data on Australians aged ≥65 years (23vPPV funded) and 50-64 years (23vPPV not funded). (edu.au)
  • VAX-24 is the biotech's lead, broad-spectrum, 24-valent pneumococcal conjugate vaccine (PCV) candidate, being evaluated to prevent invasive pneumococcal disease. (streetwisereports.com)
  • This report describes case notification data for measles, pertussis, rubella, Haemophilus influenzae type b invasive infection, invasive meningococcal disease (IMD), mumps, tetanus and invasive pneumococcal disease (IPD) in NSW, Australia, in 2012 and provides comparison with recent trends. (who.int)
  • 1 On receipt of a case notification, a public health unit surveillance officer determines whether or not the case notification meets the definition of a case of vaccine-preventable disease according to national criteria 2 and if so enters data gathered on each case into the NSW Notifiable Conditions Information Management System (NCIMS). (who.int)
  • The annual rate of new vaccine introductions declined precipitously when the COVID-19 pandemic started, from 48 in 2019 to 15 in 2020 before rising to 26 in 2021. (medscape.com)
  • By ensuring that infants receive the recommended doses of the pneumococcal vaccine, parents can significantly reduce the risk of their child developing this life-threatening infection. (total-health-care.com)
  • Fisher said the three infants also received two unrelated other vaccines as part of routine immunizations. (infiniteunknown.net)
  • The immune response to conjugate vaccine is proving sufficiently robust-post-marketing studies now provide evidence that three doses will prove as immunogenic as four in healthy infants. (bcmj.org)
  • Objective: To evaluate the impact and effectiveness of the 23-valent polysaccharide pneumococcal vaccine (23vPPV) in ≥65-year-old Australians in the context of concurrent 7-valent pneumococcal conjugate vaccine (7vPCV) use in infants. (edu.au)
  • Greater reductions in IPD in ≥65-year-olds would be expected from the indirect effects of using 13-valent pneumococcal conjugate vaccine in infants (introduced for Australian infants in 2011) and an increase in 23vPPV coverage. (edu.au)
  • The overall rate for pneumococcal bacteremia in some Native American populations can be six times the rate of the general population (5). (cdc.gov)
  • In a recent population-based study, all persons 55-64 years old with pneumococcal bacteremia had at least one of these chronic conditions (4). (cdc.gov)
  • By getting vaccinated, individuals can lower their chances of developing pneumococcal bacteremia and the associated complications. (total-health-care.com)
  • Pneumococcal bacteremia occurs when the pneumococcus bacterium enters the bloodstream and spreads throughout the body. (total-health-care.com)
  • For the full text of the recommendations, see Pneumococcal ACIP Vaccine Recommendations . (cdc.gov)
  • The conjugate vaccine PCV15 protects against 15 types of pneumococci. (msdmanuals.com)
  • In addition to the very young and persons greater than or equal to 65 years old, patients with certain chronic conditions are at increased risk of developing pneumococcal infection and severe pneumococcal illness. (cdc.gov)
  • These include not only monovalent, mRNA-based shots for COVID-19, but also a flu shot and a pneumococcal vaccine shot to protect against a bacterial infection in seniors 65 years and older. (yahoo.com)
  • Bogoch explained vaccines can reduce the risk or severity of infection, especially for older Canadians who are at greater risk for severe influenza, COVID and RSV infection. (yahoo.com)
  • How can you tell if you have pneumococcal infection? (hnhu.org)
  • Another pneumococcal infection is sepsis, which can lead to amputation or death. (gavi.org)
  • Pneumococcal otitis media, a middle ear infection, can result in permanent deafness. (gavi.org)
  • However, two types of vaccines are available to help prevent infection with the most common strains. (who.int)
  • Like influenza vaccine, both doses of pneumococcal vaccine for people 65 years and older are covered at 100 percent under Medicare Part B. There is no out-of-pocket expense for people on Medicare. (immunize.org)
  • Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. (bvsalud.org)
  • This substudy from the phase III, randomized, double-blind, placebo-controlled BLISS-76 trial evaluated the effects of belimumab on preexisting antibody levels against pneumococcal, tetanus , and influenza antigens in patients with SLE. (bvsalud.org)
  • This analysis included a subset of patients who had received pneumococcal or tetanus vaccine within 5 years or influenza vaccine within 1 year of study participation. (bvsalud.org)
  • Consistent with preservation of the memory B cell compartment with belimumab treatment , the proportions of patients maintaining antibody responses to pneumococcal, tetanus , and influenza antigens were not reduced. (bvsalud.org)
  • Treatment with belimumab did not affect the ability of patients with SLE to maintain antibody titers to previous pneumococcal, tetanus , and influenza immunizations . (bvsalud.org)
  • This reflects a decade of progress and hard work by countries and Vaccine Alliance partners to support the introduction of pneumococcal vaccine into routine immunisation programmes and to scale up coverage. (gavi.org)
  • Pneumococcus can colonize the upper respiratory tract, most commonly in young children, and is transmitted to others through contact with respiratory droplets from a person with pneumococcal colonization in the upper respiratory tract ( 1 ). (cdc.gov)
  • As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death. (medlineplus.gov)
  • There are 2 types of pneumococcal vaccines: conjugate and polysaccharide. (merckmanuals.com)
  • Two types of pneumococcal vaccines are available: conjugate and polysaccharide. (msdmanuals.com)
  • It is estimated that the pneumococcal AMC could prevent more than 1.5 million childhood deaths by 2020. (wikipedia.org)
  • At least 100 pneumococcal serotypes were documented as of 2020 ( 5 - 7 ). (cdc.gov)
  • The new generation of whole-cell vaccines is based on an unencapsulated serotype that allows the expression of many bacterial antigens at a lower cost than a recombinant vaccine. (mdpi.com)
  • Current pneumococcal vaccines use the pneumococcal capsular polysaccharides as antigens to generate serotype-specific antibodies, which facilitate serotype-specific clearance of pneumococci through opsonophagocytosis ( 4 ). (cdc.gov)
  • This report describes the status of introductions globally for eight World Health Organization (WHO)-recommended new and underutilized vaccines, comprising 10 individual vaccine antigens. (medscape.com)
  • Antibodies to vaccine antigens were tested at baseline and Week 52, and percentage changes in antibody levels from baseline and proportions of patients maintaining levels at Week 52 were assessed. (bvsalud.org)
  • The introduction of the PCV vaccine comes as COVID-19 threatens to roll back hard-earned gains across many childhood routine immunisation programmes. (unicef.org)
  • The results of the demonstration program showed that the PCV immunisation coverage during that period was above 80% on average, indicating that these vaccines were well received by the community. (unicef.org)
  • By the end of 2019, 60 Gavi-supported countries - more than 80% of those eligible to do so - had introduced pneumococcal conjugate vaccine (PCV) into their routine immunisation programmes. (gavi.org)
  • But they also found that the incidence of IPD caused by strains not included in the vaccine increased by 40 percent. (contemporarypediatrics.com)
  • Surveillance will continue along with extra efforts to ensure that all available isolates from IPD cases are serotyped so that it can be determined if there is any increase in the rate of cases caused by vaccine-preventable strains among immunized children. (bcmj.org)
  • Moreover, the mice developed protection not only against the pneumococcal strain/type from which the particles were isolated but also against other pneumococcal strains/types. (nordiclifescience.org)
  • The World Health Organization recommends that a switch in the vaccine used in any national PCV programme should be considered if the epidemiology of IPD changes significantly. (otago.ac.nz)
  • Conducted in a country without routine pneumococcal conjugate vaccine (PCV) use, allowing inclusion of an unvaccinated control group and measurement of the reduction in carriage afforded by the reduced-dose schedules. (bmj.com)
  • Vaccine introduction data for DTPCV4 was unavailable for 2016. (medscape.com)
  • Persons who have had an allergic reaction to a previous pneumococcal vaccine. (hnhu.org)
  • The guarantee is linked to safety and efficacy standards that the vaccine must meet and is structured in a way to allow several firms to compete to develop and produce the best possible new product. (wikipedia.org)
  • Studies assessing the safety, immunogenicity, and efficacy of pneumococcal conjugate vaccines in both healthy and high-risk 6 - 17-year-old children and adolescents are covered and the potential impact of PCV-13 in these populations is discussed. (uzh.ch)
  • The World Health Organization (WHO) recommends the use of the conjugate vaccine in the routine immunizations given to children. (wikipedia.org)
  • An observational study was undertaken in a cohort of 16 older individuals with chronic lung disorders to measure immunogenicity before and after the first, second, and third immunizations with the 23-valent pneumococcal polysaccharide vaccine. (physiciansweekly.com)
  • When compared to the first and second immunizations, serotype-specific OIs did not differ following the third vaccine. (physiciansweekly.com)